Share-based Payment Arrangement, Expense of KalVista Pharmaceuticals, Inc. from 31 Dec 2013 to 31 Jul 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
KalVista Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2013 to 31 Jul 2025.
  • KalVista Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Jul 2025 was $5,379,000, a 77% increase year-over-year.
  • KalVista Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $12,291,000, a 44% decline from 2023.
  • KalVista Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $21,915,000, a 121% increase from 2022.
  • KalVista Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $9,922,000, a 10% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

KalVista Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $5,379,000 +$2,339,000 +77% 01 May 2025 31 Jul 2025 10-Q 11 Sep 2025 2026 Q1
Q2 2024 $3,040,000 -$214,000 -6.6% 01 May 2024 31 Jul 2024 10-Q 11 Sep 2025 2026 Q1
Q2 2023 $3,254,000 +$612,000 +23% 01 May 2023 31 Jul 2023 10-Q 05 Sep 2024 2025 Q1
Q2 2022 $2,642,000 -$153,000 -5.5% 01 May 2022 31 Jul 2022 10-Q 07 Sep 2023 2024 Q1
Q2 2021 $2,795,000 +$1,607,000 +135% 01 May 2021 31 Jul 2021 10-Q 08 Sep 2022 2023 Q1
Q2 2020 $1,188,000 +$114,000 +11% 01 May 2020 31 Jul 2020 10-Q 09 Sep 2021 2022 Q1
Q2 2019 $1,074,000 +$727,000 +210% 01 May 2019 31 Jul 2019 10-Q 14 Sep 2020 2021 Q1
Q2 2018 $347,000 +$126,000 +57% 01 May 2018 31 Jul 2018 10-Q 09 Sep 2019 2020 Q1
Q2 2017 $221,000 -$91,000 -29% 01 May 2017 31 Jul 2017 10-Q 14 Sep 2018 2019 Q1
Q3 2016 $1,303,000 $282,000 -$7,000 -2.4% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2016 2016 Q3
Q2 2016 $1,310,000 $312,000 +$275,000 +743% 01 Apr 2016 30 Jun 2016 10-Q 12 Aug 2016 2016 Q2
Q1 2016 $1,035,000 $368,000 +$250,000 +212% 01 Jan 2016 31 Mar 2016 10-Q 12 May 2016 2016 Q1
Q4 2015 $785,000 $341,000 +$169,000 +98% 01 Oct 2015 31 Dec 2015 10-K 30 Mar 2016 2015 FY
Q3 2015 $616,000 $289,000 +$189,000 +189% 01 Jul 2015 30 Sep 2015 10-Q 08 Nov 2016 2016 Q3
Q2 2015 $427,000 $37,000 -$13,000 -26% 01 Apr 2015 30 Jun 2015 10-Q 12 Aug 2016 2016 Q2
Q1 2015 $440,000 $118,000 +$59,000 +100% 01 Jan 2015 31 Mar 2015 10-Q 12 May 2016 2016 Q1
Q4 2014 $381,000 $172,000 01 Oct 2014 31 Dec 2014 10-K 30 Mar 2016 2015 FY
Q3 2014 $100,000 01 Jul 2014 30 Sep 2014 10-Q 12 Nov 2015 2015 Q3
Q2 2014 $50,000 01 Apr 2014 30 Jun 2014 10-Q 13 Aug 2015 2015 Q2
Q1 2014 $59,000 01 Jan 2014 31 Mar 2014 10-Q 21 May 2015 2015 Q1

KalVista Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $12,291,000 -$9,624,000 -44% 01 May 2024 30 Apr 2025 10-K 10 Jul 2025 2025 FY
2023 $21,915,000 +$11,993,000 +121% 01 May 2023 30 Apr 2024 10-K 10 Jul 2025 2025 FY
2022 $9,922,000 -$1,164,000 -10% 01 May 2022 30 Apr 2023 10-K 11 Jul 2024 2024 FY
2021 $11,086,000 +$3,968,000 +56% 01 May 2021 30 Apr 2022 10-K 11 Jul 2024 2024 FY
2020 $7,118,000 +$2,670,000 +60% 01 May 2020 30 Apr 2021 10-K 10 Jul 2023 2023 FY
2019 $4,448,000 +$1,482,000 +50% 01 May 2019 30 Apr 2020 10-K 07 Jul 2022 2022 FY
2018 $2,966,000 +$1,906,000 +180% 01 May 2018 30 Apr 2019 10-K 13 Jul 2021 2021 FY
2017 $1,060,000 +$666,000 +169% 01 May 2017 30 Apr 2018 10-K 01 Jul 2020 2020 FY
2016 $394,000 -$391,000 -50% 01 May 2016 30 Apr 2017 10-K 16 Jul 2019 2019 FY
2015 $785,000 +$404,000 +106% 01 Jan 2015 31 Dec 2015 10-K 30 Mar 2016 2015 FY
2014 $381,000 +$143,000 +60% 01 Jan 2014 31 Dec 2014 10-K 30 Mar 2016 2015 FY
2013 $238,000 01 Jan 2013 31 Dec 2013 10-K 30 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.